Krystal Biotech, Inc.
In the published model solve dated 2026-Q2, anchored at $358.33, Krystal Biotech, Inc. (KRYS) is priced for today's economics sustained for ~14.0 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
• Krystal is the rare biotech that is already profitable, selling Vyjuvek, an approved gene therapy for a rare skin disease, at a 95% gross margin and funding a deep pipeline out of its own cash rather than dilutive raises [Source: Krystal Q1 2026 results, May 2026]. • The price is the issue, not the business: at roughly 57 times operating income it embeds something like fourteen years of ceiling-rate growth, a durability bet only a small fraction of fast-growers have ever delivered. • Watch the
Is KRYS overvalued? See what's priced in →
352 institutional managers reported holding KRYS in 13F filings for the quarter ended 2026-03-31. Together they hold about 92% of the company; the top 10 hold 63%. 65 opened new positions that quarter. Held by FMR (Fidelity), BlackRock, Vanguard Group, among others. On the short side, 3.1M shares were sold short as of the 2026-06-15 count, about 10% of shares outstanding (10.9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
KRYS's share count grew 31.9% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at KRYS over the trailing three years. Absence is a fact about the company, not a signal. 7 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
KRYS's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2022-08-09 | -5.2% | -17.8% |
| 2023-02-28 | +4.4% | +1.1% |
| 2023-11-07 | -10.7% | +18.3% |
| 2024-05-07 | +0.4% | +19.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
KRYS's latest 8-K filings: 2026-07-21 (items 8.01, 9.01); 2026-05-20 (items 5.07); 2026-05-04 (items 9.01); 2026-02-17 (items 2.02); 2026-01-12 (items 2.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.